Daclatasvir Dihydrochloride Intermediate CAS 1007882-23-6 Maʻemaʻe >98.0% (HPLC)
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui o Daclatasvir Dihydrochloride Intermediate (CAS: 1007882-23-6) me ke kūlana kiʻekiʻe.Hiki iā Ruifu Chemical ke hāʻawi i ka hāʻawi honua, ke kumukūʻai hoʻokūkū, ka liʻiliʻi a me ka nui o ka nui.E kūʻai aku iā Daclatasvir Dihydrochloride Intermediates,Please contact: alvin@ruifuchem.com
| Inoa Kimia | Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) |
| Nā huaʻōlelo like | Daclatasvir Intermediate Ⅱ;Dacaltasvir Intermediate 02;Daclatasvir T-Butyl Ester;Bis(2-Methyl-2-Propanyl) (2S,2'S)-2,2'-[4,4'-Biphenyldiylbis(1H-Imidazole-4,2-diyl)]di(1-Pyrrolidinecarboxylate);Di-tert-butyl 2,2′-([1,1′-Biphenyl]-4,4′-diylbis(1H-Imidazole-5,2-diyl))(2S,2'S)-bis(Pyridineidine-1- Carboxylate);(2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-Imidazole-5,2-diyl)bis-1-Pyrrolidinecarboxylic Acid 1,1'-Bis (1,1-Dimethylethyl) Ester;ʻO ka haumia ʻo Daclatasvir 4 |
| Kūlana Kūʻai | Ma ke Kahua, Hana Hana Kūʻai |
| Helu CAS | 1007882-23-6 |
| ʻĀpana Molekala | C40H51ClN8O6 |
| Kaumaha Molecular | 775.35 g/mol |
| Lae paila | 890.2±65.0 ℃ ma 760 mmHg |
| ʻO ka mānoanoa | 1.220±0.06 g/cm3 |
| COA & MSDS | Loaʻa |
| Ke kumu | Shanghai, Kina |
| Māhele | Ka waena o Daclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Brand | Kemika Ruifu |
| Nā mea | Nā kikoʻī | Nā hualoaʻa |
| Ka nana aku | Melemele māmā i ka pauda melemele | Pauda Melemele Māmā |
| Nalo ma ka maloo | <1.00% | 0.65% |
| ʻO ka haumia hoʻokahi kiʻekiʻe | <1.00% | 0.45% |
| Huina paumaele | <2.00% | 1.24% |
| Maʻemaʻe / Kaʻina Hanana | >98.0% (HPLC) | 98.76% |
| Infrared Spectrum | Kūlike me ka Hoʻolālā | Hoʻokō |
| 1H NMR Spectrum | Kūlike me ka Hoʻolālā | Hoʻokō |
| Ka hopena | Ua hoʻāʻo ʻia ka huahana a hoʻokō me nā kikoʻī i hāʻawi ʻia | |
| Palapala noi | Ka waena o Daclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Pūʻolo:ʻO ka ʻōmole Fluorinated, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E hoʻopaʻa paʻa i ka pahu a mālama i loko o kahi hale kūʻai maloʻo a me ka makani maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
Pehea e kūʻai ai?E ʻoluʻolu e kelepona maiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 mau makahiki ʻike?Loaʻa iā mākou ma mua o 15 mau makahiki o ka ʻike i ka hana ʻana a me ka hoʻokuʻu ʻana aku i kahi ākea ākea o nā intermediates pharmaceutical kiʻekiʻe a i ʻole nā kemika maikaʻi.
Mākeke Nui?E kūʻai aku i ka mākeke kūloko, ʻAmelika ʻĀkau, ʻEulopa, India, Korea, Iapana, Australia, etc.
Nā pono?ʻO ke kūlana kiʻekiʻe, ke kumukūʻai kūpono, nā lawelawe ʻoihana a me ke kākoʻo ʻenehana, ka lawe wikiwiki ʻana.
ʻAno maikaʻiHōʻoiaʻiʻo?Pūnaehana hoʻomalu maikaʻi koʻikoʻi.ʻO nā lako ʻoihana no ka nānā ʻana ʻo NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Nā laʻana?Hāʻawi ka hapa nui o nā huahana i nā laʻana manuahi no ka loiloi maikaʻi, pono e uku ʻia ke kumukūʻai e nā mea kūʻai aku.
Hooia Hale Hana?Welina mai ka loiloi hale hana.E ʻoluʻolu e hoʻopaʻa manawa ma mua.
MOQ?ʻAʻohe MOQ.ʻAe ʻia ke kauoha liʻiliʻi.
Manawa Hoʻouna? Inā i loko o ka waihona, ʻekolu lā hoʻouna ʻia.
Kaʻahele?Ma ka Express (FedEx, DHL), ma ka Air, ma ke Kai.
Nā palapala?Ma hope o ka lawelawe kūʻai: COA, MOA, ROS, MSDS, etc.
Hoʻohui Kuʻuna?Hiki ke hāʻawi i nā lawelawe synthesis maʻamau e kūpono i kāu mau pono noiʻi.
Kūkākūkā uku?E hoʻouna mua ʻia ka invoice Proforma ma hope o ka hōʻoia ʻana o ke kauoha, hoʻopili ʻia kā mākou ʻike panakō.Uku e T/T (Telex Transfer), PayPal, Western Union, etc.
Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) (CAS: 1007882-23-6) he mea waena o Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Ua loaʻa iā Daclatasvir (Daklinza) ke kūlana "priority review", i hui pū ʻia me Sorafenib no ka mālama ʻana i nā maʻi maʻi genotype III me ka maʻi hepatitis C. ka maʻi me ka ʻole o ka hui pū ʻana me interferon a i ʻole ribavirin.ʻO Interferon a me Ribavirin nā lāʻau ʻelua i ʻae ʻia e FDA no ka mālama ʻana i ka maʻi maʻi hepatitis C.ʻO ka maʻi Hepatitis C he maʻi maʻi maʻi e hiki ai ke hoʻomake i ka ate, ka hopena o ka emi ʻana o ka hana o ka ate a i ʻole ka hāʻule ʻole o ka ate.ʻO ka hapa nui o nā maʻi i loaʻa i ka maʻi hepa C ʻaʻohe hōʻailona a hiki i ka ʻike ʻia ʻana o ka pōʻino o ke ake, a he mau makahiki paha.Ma ke ao holoʻokoʻa, ʻo ka genotype III hepatitis C ka lua o ka genotype maʻamau o ka hepatitis C ma hope o ka genotype 1 hepatitis C a ua manaʻo ʻia ʻo ia kekahi o nā maʻi genotype refractory loa.ʻO Daklinza kahi pan-genotype NS5A replication complex inhibitor, me ka ikaika o ka pale ʻana i ka replication RNA a me ka hui viral, ʻelua hopena antiviral.No nā haʻawina in vitro, ua hōʻike ʻia ʻo Daklinza i ka hopena anti-viral e kūʻē i ka maʻi hepatitis C genotype 1-6.Hoʻopili ʻia ʻo Daklinza me kahi ʻōlelo aʻo e hiki ke hoʻemi ʻia ka puʻuwai puʻuwai i ka hui pū ʻana o amiodarone, Daklinza a me Sofosbuvir.ʻO Daklinza kahi papa haʻi waha me ka nui o 60 mg i ʻōlelo ʻia no 1 mau manawa/d, i hui pū me Sofosbuvir no ka huina o 12 pule.
Hui noiʻi a hoʻomohala: Bristol-Myers Squibb.
Patent Literature: WO 2008021927A2 (ʻAukake 9, 2007).
Ka manawa kūʻai: Iulai 24, 2015 i helu ʻia ma ʻAmelika Hui Pū ʻIa, ʻo Daklinza inoa inoa.
Nā hōʻailona: Hoʻohana pū ʻia me Sofosbuvir no ka mālama ʻana i ka maʻi hepatitis C (HCV) genotype 3 mau loa.
Mechanism o ka hana: HCV nonstructural protein 5A (NS5A) inhibitors.Nā hopena ʻino: ke poʻo a me ka luhi.
Hoʻokumu a me nā kikoʻī: Papa, 30 a me 60mg.
